{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:51:59Z","timestamp":1761864719284,"version":"3.28.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,23]]},"DOI":"10.7759\/cureus.74316","type":"journal-article","created":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T18:17:11Z","timestamp":1732385831000},"source":"Crossref","is-referenced-by-count":1,"title":["Lingual Necrosis in the Setting of Giant Cell Arteritis"],"prefix":"10.7759","author":[{"given":"Nivedha","family":"Balaji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Ignatowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandus","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreya","family":"Kuturu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishali","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59554","article-title":"Giant cell arteritis with bilateral central retinal artery occlusion and tongue necrosis","volume":"16","author":"Brar AS","year":"2024","unstructured":"Brar AS, Nanda R, Narayanan R, Padhy SK. Giant cell arteritis with bilateral central retinal artery occlusion and tongue necrosis. Cureus. 2024, 16:e59554. 10.7759\/cureus.59554","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02433-y","article-title":"Giant cell arteritis: reviewing the advancing diagnostics and management","volume":"37","author":"Bilton EJ","year":"2023","unstructured":"Bilton EJ, Mollan SP. Giant cell arteritis: reviewing the advancing diagnostics and management. Eye (Lond). 2023, 37:2365-73. 10.1038\/s41433-023-02433-y","journal-title":"Eye (Lond)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2174\/1573397115666190227194014","article-title":"Giant cell arteritis (GCA): pathogenesis, clinical aspects and treatment approaches","volume":"15","author":"Ciofalo A","year":"2019","unstructured":"Ciofalo A, Gulotta G, Iannella G, et al.. Giant cell arteritis (GCA): pathogenesis, clinical aspects and treatment approaches. Curr Rheumatol Rev. 2019, 15:259-68. 10.2174\/1573397115666190227194014","journal-title":"Curr Rheumatol Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-023-06465-z","article-title":"Tongue necrosis secondary to giant cell arteritis, successfully treated with tocilizumab: a case report","volume":"24","author":"Cho YM","year":"2023","unstructured":"Cho YM, El Khoury L, Paramo J, Horowitz DM, Li JY, Kello N. Tongue necrosis secondary to giant cell arteritis, successfully treated with tocilizumab: a case report. BMC Musculoskelet Disord. 2023, 24:382. 10.1186\/s12891-023-06465-z","journal-title":"BMC Musculoskelet Disord"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223482","article-title":"2022 American College of Rheumatology\/EULAR classification criteria for Takayasu arteritis","volume":"81","author":"Grayson PC","year":"2022","unstructured":"Grayson PC, Ponte C, Suppiah R, et al.. 2022 American College of Rheumatology\/EULAR classification criteria for Takayasu arteritis. Ann Rheum Dis. 2022, 81:1654-60. 10.1136\/ard-2022-223482","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-244948","article-title":"Giant cell arteritis complicated by tongue necrosis and bilateral cerebellar ischaemic stroke","volume":"14","author":"Rose EC","year":"2021","unstructured":"Rose EC, Carroll LS, Evans S, Mason A. Giant cell arteritis complicated by tongue necrosis and bilateral cerebellar ischaemic stroke. BMJ Case Rep. 2021, 14:e244948. 10.1136\/bcr-2021-244948","journal-title":"BMJ Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich B","year":"2020","unstructured":"Hellmich B, Agueda A, Monti S, et al.. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020, 79:19-30. 10.1136\/annrheumdis-2019-215672","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-1090-y","article-title":"Practice points for ophthalmologists from the 2020 British Society for Rheumatology Giant Cell Arteritis guidelines","volume":"35","author":"Mollan SP","year":"2021","unstructured":"Mollan SP, Grech O, O'Sullivan E, Mackie SL. Practice points for ophthalmologists from the 2020 British Society for Rheumatology Giant Cell Arteritis guidelines. Eye (Lond). 2021, 35:699-701. 10.1038\/s41433-020-1090-y","journal-title":"Eye (Lond)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"7","author":"Villiger PM","year":"2016","unstructured":"Villiger PM, Adler S, Kuchen S, et al.. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016, 7:1921-7. 10.1016\/S0140-6736(16)00560-2","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2022-0041","article-title":"An update on the clinical approach to giant cell arteritis","volume":"22","author":"Piccus R","year":"2022","unstructured":"Piccus R, Hansen MS, Hamann S, Mollan SP. An update on the clinical approach to giant cell arteritis. Clin Med (Lond). 2022, 22:107-11. 10.7861\/clinmed.2022-0041","journal-title":"Clin Med (Lond)"},{"key":"ref11","article-title":"Glucocorticoid dose dependent downregulation of glucocorticoid receptors in patients with rheumatic diseases","volume":"27","author":"Sanden S","year":"2000","unstructured":"Sanden S, Tripmacher R, Weltrich R, Rohde W, Hiepe F, Burmester GR, Buttgereit F. Glucocorticoid dose dependent downregulation of glucocorticoid receptors in patients with rheumatic diseases. J Rheumatol. 2000, 27:1265-70.","journal-title":"J Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.8.718","article-title":"Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology","volume":"61","author":"Buttgereit F","year":"2002","unstructured":"Buttgereit F, da Silva JA, Boers M, et al.. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002, 61:718-22. 10.1136\/ard.61.8.718","journal-title":"Ann Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v3.i6.484","article-title":"Giant cell arteritis: current treatment and management","volume":"3","author":"Ponte C","year":"2015","unstructured":"Ponte C, Rodrigues AF, O'Neill L, Luqmani RA. Giant cell arteritis: current treatment and management. World J Clin Cases. 2015, 3:484-94. 10.12998\/wjcc.v3.i6.484","journal-title":"World J Clin Cases"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone JH","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, et al.. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017, 377:317-28. 10.1056\/NEJMoa1613849","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00038-2","article-title":"Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial","volume":"3","author":"Stone JH","year":"2021","unstructured":"Stone JH, Han J, Aringer M, et al.. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. Lancet Rheumatol. 2021, 3:328-36. 10.1016\/S2665-9913(21)00038-2","journal-title":"Lancet Rheumatol"},{"key":"ref16","article-title":"A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA)","volume":"19","author":"Spiera RF","year":"2001","unstructured":"Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, Paget SA. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001, 19:495-501.","journal-title":"Clin Exp Rheumatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman GS","year":"2007","unstructured":"Hoffman GS, Cid MC, Rendt-Zagar KE, et al.. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007, 146:621-30. 10.7326\/0003-4819-146-9-200705010-00004","journal-title":"Ann Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.082115","article-title":"A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects","volume":"67","author":"Mart\u00ednez-Taboada VM","year":"2008","unstructured":"Mart\u00ednez-Taboada VM, Rodr\u00edguez-Valverde V, Carre\u00f1o L, et al.. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2008, 67:625-30. 10.1136\/ard.2007.082115","journal-title":"Ann Rheum Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/901795","article-title":"Tongue necrosis as an initial manifestation of giant cell arteritis: case report and review of the literature","volume":"2015","author":"Zaragoza JR","year":"2015","unstructured":"Zaragoza JR, Vernon N, Ghaffari G. Tongue necrosis as an initial manifestation of giant cell arteritis: case report and review of the literature. Case Rep Rheumatol. 2015, 2015:901795. 10.1155\/2015\/901795","journal-title":"Case Rep Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2023-254888","article-title":"Tongue necrosis secondary to giant cell arteritis","volume":"16","author":"Cant\u00f3n De Seoane J","year":"2023","unstructured":"Cant\u00f3n De Seoane J, Guti\u00e9rrez Gu\u00e9dez LA, Rodr\u00edguez Cambr\u00f3n AB, Burgos F. Tongue necrosis secondary to giant cell arteritis. BMJ Case Rep. 2023, 16:254888. 10.1136\/bcr-2023-254888","journal-title":"BMJ Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/317604-lingual-necrosis-in-the-setting-of-giant-cell-arteritis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T18:17:12Z","timestamp":1732385832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/317604-lingual-necrosis-in-the-setting-of-giant-cell-arteritis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,23]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.74316","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,23]]}}}